期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Experimental and clinical assessment of percutaneous hepatic quantified ethanol injection in treatment of hepatic carcinoma 被引量:27
1
作者 Li-WuLin Xue-YingLin Yi-MiHe Shang-DaGao En-ShengXue Xiao-DongLin Li-YunYu 《World Journal of Gastroenterology》 SCIE CAS CSCD 2004年第21期3112-3117,共6页
AIM: To detect the relationship between absolute ethanol injection quantity, the interval and formation of fibreboard, the curative effect in treatment of hepatocarcinoma and to evaluate the clinical application of pe... AIM: To detect the relationship between absolute ethanol injection quantity, the interval and formation of fibreboard, the curative effect in treatment of hepatocarcinoma and to evaluate the clinical application of percutaneous hepatic quantified ethanol injection (PHQEI) in treatment of hepatic carcinoma (HCC).METHODS: (1) Experimental study: Twenty-four human hepatic carcinoma SMMC-7721 xenografted nude mice were randomly divided into three groups: group A injected with quantified ethanol at short intervals (QESI), group B with quantified ethanol at long intervals (QELI) and group C with a small quantity of ethanol at long intervals (SQLI). The tumor tissues were sent for patho-histology and electron microscopic examinations. The diameters of tumors were measured with high frequency ultrasound before and after therapies and tumor growth index (TGI) was calculated. (2) Clinical study: Tumors of 122 cases of pathologically proved HCC were injected with quantified ethanol guided by ultrasound every 3-5 d 4-10 times per period of treatment. The quantity of ethanol was calculated according to the regressive equations where Y = 2.885X when the mass was ≤5 cm in diameter and Y = 1.805X when the mass was >5 cm in diameter (X is the maximal diameter of the mass with the unit cm, Y is the ethanol quantity with the unit mL). The survival rates of 1, 2, 3 and 4 years and recurrent rates in situas well as dystopia in the liver were calculated.RESULTS: (1) Experimental study: TGI of QESI group (0.072:1:0.018) and QELI group (0.094:1:0.028) was apparently lower than that of SQLI group (1.982:1:0.482) (P<0.01). TGI of QESI group seemed to be lower than that of QELI group, but it was not markedly different (P>0.05) between two groups. Severe degeneration and necrosis could be seen in QESI group by patho-histology examination. Coagulative necrosis could be seen in most tumors of QESI group and there were no residual cancer cells under electronic microscope, while the residual cancer and inflammatory cells and fibre tissues cou 展开更多
关键词 临床实验 经皮注射法 酒精 量化 肝脏疾病 肝癌 肿瘤 消化系统
下载PDF
Percutaneous Ethanol Intratumoral Injection for Treatment of Small Primary Liver Cancer:Summary of 240 Cases 被引量:4
2
作者 GUOJia CHENHan 《The Chinese-German Journal of Clinical Oncology》 CAS 2002年第2期75-77,共3页
Objective To evaluate the therapeutic effects of percutaneous ethanol intratumoral injection (PEIT) for treatment of small primary liver cancer (SPLC).Methods 240 patients with surgically or pathologically proved SPLC... Objective To evaluate the therapeutic effects of percutaneous ethanol intratumoral injection (PEIT) for treatment of small primary liver cancer (SPLC).Methods 240 patients with surgically or pathologically proved SPLC ( < 3 cm in diameter) were treated by PEIT ( under the guidance of B-ultrasound) . Of the" 240 patients, 163 had recurrent liver cancer, 55 had inoperable liver cancer because of cardiac, pulmonary, hepatic and renal dysfunctions or due to the close proximity of tumor to the major vessels, and 22 refused to receive surgical resection. In 40 patients who received surgical resection after PEIT treatment, the resected tumors were pathologically evaluated for necrotic status and the patients were followed up postoperatively.Results Postoperative 1-, 2- and 3-year survival rate of the 240 patients was 94.9% , 84.2% and 66.3% respectively. Conclusion PEIT can be used as a non-invasive treatment for SPLC, and preoperative PEIT appears to be helpful in reducing recurrence of postoperative liver cancer. 展开更多
关键词 primary liver cancer percutaneous ethanol INTRATUMORAL INJECTION
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部